TScan Therapeutics
TCRX
29 hedge funds and large institutions have $44.4M invested in TScan Therapeutics in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 7 closing their positions.
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
7% more funds holding
Funds holding: 27 → 29 (+2)
0.97% less ownership
Funds ownership: 53.91% → 52.94% (-0.97%)
47% less capital invested
Capital invested by funds: $83.5M → $44.4M (-$39.1M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$721K |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$386K |
| 3 |
NFGH
Nan Fung Group Holdings
Kai Tak,
Hong Kong
|
+$351K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$289K |
| 5 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
+$156K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.49M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.16M |
| 3 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$834K |
| 4 |
CCM
CAAS Capital Management
New York
|
-$356K |
| 5 |
Two Sigma Investments
New York
|
-$190K |
TCRX Hedge Fund Activity: Q4 2021 in Review
29 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q4 2021, worth a combined $44.4M — down 47% from $83.5M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new TCRX positions and 7 closed out — a net gain of 3 holders — while 2 added to existing stakes and 6 trimmed.
The largest buyer was Woodline Partners, opening a new position worth an estimated $721K. The largest seller was Vanguard Group, cutting an estimated $1.49M.
- 29 institutional investors held TScan Therapeutics (TCRX) as of Q4 2021, up from 27 in Q3 2021.
- Funds reported $44.4M of TScan Therapeutics stock for Q4 2021, down 47% quarter-over-quarter.
- 10 funds opened new TScan Therapeutics positions in Q4 2021 and 7 closed out, a net change of +3 holders.
- The largest TScan Therapeutics buyer in Q4 2021 was Woodline Partners, an estimated $721K added.
- The largest TScan Therapeutics seller in Q4 2021 was Vanguard Group, an estimated $1.49M sold.
Based on aggregated 13F filings for Q4 2021.